Annual report [Section 13 and 15(d), not S-K Item 405]

Summary of Significant Accounting Policies - Segment Information Significant Expense Categories (Details)

v3.25.1
Summary of Significant Accounting Policies - Segment Information Significant Expense Categories (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating expenses:    
Total research and development $ 3,530,913 $ 1,728,078
General and administrative expenses 8,696,335 3,718,841
Total operating expenses 12,227,248 5,446,919
Exchange loss, net 30,787  
Net loss before income taxes 12,349,724 5,296,015
Single reportable segment    
Operating expenses:    
Clinical 1,153,345 112,196
Chemical, manufacturing and controls 710,055 312,691
Research and preclinical 505,750 267,803
Regulatory 20,065 186,395
Other research and development costs 1,141,698 848,993
Total research and development 3,530,913 1,728,078
General and administrative expenses 8,696,335 3,718,841
Total operating expenses 12,227,248 5,446,919
Interest expense (income), net 92,192 (150,904)
Exchange loss, net 30,787  
Net loss before income taxes $ 12,350,227 $ 5,296,015